Literature DB >> 35916978

G-protein-coupled receptor 124 promotes osteogenic differentiation of BMSCs through the Wnt/β-catenin pathway.

Jiangwei Ma1, Pu Chen2, Rong Wang3.   

Abstract

Osteoporosis occurs frequently in women after menopause and old age, and it is very easy to cause osteoporotic fractures, resulting in disability and death. In osteoporosis patients, the potential of bone marrow mesenchymal stem cells (BMSCs) to differentiate into osteoblasts gradually is inhibited, leading to decreased new bone formation. In the current study, the potential effect of G-protein-coupled receptor 124 (GPR124) on the osteoblastic differentiation of BMSCs was determined. BMSCs were isolated and cultured in osteogenic media to induced osteogenic differentiation. Then, osteogenic differentiation was evaluated by Alizarin Red staining and ALP activity. The expression of osteogenic differentiation biomarkers, and Wnt/β-catenin signaling were determined by qRT-PCR and Western blotting. The results indicated that the expression of GPR124 was significantly increased during osteogenic differentiation of BMSCs. Moreover, GPR124 knockdown significantly inhibited osteoblastic differentiation and GPR124 overexpression promoted osteoblastic differentiation of BMSCs. GPR124 knockdown suppressed the activation of Wnt/β-catenin signaling pathway. What's more, the increased osteogenic differentiation induced by GPR124 overexpression was abolished by the inhibitor of Wnt/β-catenin pathway and Wnt7a knockdown. Taken together, GPR124 promotes osteogenic differentiation of BMSCs through the Wnt/β-catenin pathway and may serve as a potential target for enhancing osteogenesis of osteoporosis patients.
© 2022. The Society for In Vitro Biology.

Entities:  

Keywords:  BMSC; GPR124; Osteogenic differentiation; Osteoporosis; Wnt/β-catenin

Mesh:

Substances:

Year:  2022        PMID: 35916978     DOI: 10.1007/s11626-022-00684-9

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.723


  22 in total

Review 1.  Parathyroid hormone analogues in the treatment of osteoporosis.

Authors:  Marius E Kraenzlin; Christian Meier
Journal:  Nat Rev Endocrinol       Date:  2011-07-12       Impact factor: 43.330

Review 2.  Wnt/beta-catenin signaling: components, mechanisms, and diseases.

Authors:  Bryan T MacDonald; Keiko Tamai; Xi He
Journal:  Dev Cell       Date:  2009-07       Impact factor: 12.270

Review 3.  Osteoporosis and the Ageing Skeleton.

Authors:  Terry J Aspray; Tom R Hill
Journal:  Subcell Biochem       Date:  2019

4.  Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling.

Authors:  So-Young Hwang; Xianming Deng; Sanguine Byun; Chan Lee; Seung-Joo Lee; Hyunsuk Suh; Jianming Zhang; Qiaofeng Kang; Ting Zhang; Kenneth D Westover; Anna Mandinova; Sam W Lee
Journal:  Cell Rep       Date:  2016-06-16       Impact factor: 9.423

Review 5.  Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.

Authors:  Silvano Adami
Journal:  Curr Med Res Opin       Date:  2008-10-20       Impact factor: 2.580

6.  Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.

Authors:  Johanna Korvala; Harald Jüppner; Outi Mäkitie; Etienne Sochett; Dirk Schnabel; Stefano Mora; Cynthia F Bartels; Matthew L Warman; Donald Deraska; William G Cole; Heini Hartikka; Leena Ala-Kokko; Minna Männikkö
Journal:  BMC Med Genet       Date:  2012-04-10       Impact factor: 2.103

7.  Bone mesenchymal stem cell therapy for ovariectomized osteoporotic rats: a systematic review and meta-analysis.

Authors:  Zhenxiong Jin; Jinman Chen; Bing Shu; Yanhua Xiao; Dezhi Tang
Journal:  BMC Musculoskelet Disord       Date:  2019-11-20       Impact factor: 2.362

Review 8.  Postmenopausal osteoporosis.

Authors:  Richard Eastell; Terence W O'Neill; Lorenz C Hofbauer; Bente Langdahl; Ian R Reid; Deborah T Gold; Steven R Cummings
Journal:  Nat Rev Dis Primers       Date:  2016-09-29       Impact factor: 52.329

9.  GSK-3beta controls osteogenesis through regulating Runx2 activity.

Authors:  Fumitaka Kugimiya; Hiroshi Kawaguchi; Shinsuke Ohba; Naohiro Kawamura; Makoto Hirata; Hirotaka Chikuda; Yoshiaki Azuma; James R Woodgett; Kozo Nakamura; Ung-il Chung
Journal:  PLoS One       Date:  2007-09-05       Impact factor: 3.240

Review 10.  Wnt Pathway in Bone Repair and Regeneration - What Do We Know So Far.

Authors:  Khosrow S Houschyar; Christian Tapking; Mimi R Borrelli; Daniel Popp; Dominik Duscher; Zeshaan N Maan; Malcolm P Chelliah; Jingtao Li; Kamran Harati; Christoph Wallner; Susanne Rein; Dominik Pförringer; Georg Reumuth; Gerrit Grieb; Sylvain Mouraret; Mehran Dadras; Johannes M Wagner; Jungul Y Cha; Frank Siemers; Marcus Lehnhardt; Björn Behr
Journal:  Front Cell Dev Biol       Date:  2019-01-07
View more
  1 in total

1.  α-Hemihydrate calcium sulfate/n-hydroxyapatite combined with metformin promotes osteogenesis in vitro and in vivo.

Authors:  Sirui Liu; Haojie Fu; Yan Lv; Jing Jiao; Runying Guo; Yanyu Yang; Wenhang Dong; Hongyan Mi; Meiyue Wang; Mengzhe Liu; Rui Li
Journal:  Front Bioeng Biotechnol       Date:  2022-09-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.